Massivemarkets

AEON

AEON Biopharma, Inc.

NYSE American · usd

$0.1230-0.01 (-7.59%)
At close · 15-minute delayed
$0.1230+0.00 (+0.81%)
As of 8:00:00 PM EST on Nov 20, 2026 · After hours

AEON Biopharma, Inc. (AEON) trades at $0.1230 (-7.59%) as of 8:00:00 PM EST on Nov 20, 2026, -47.37% over the past month. Market cap is $11.2M, with 6.4 days to cover in short interest.

Stock performance

How AEON Biopharma, Inc. (AEON) stock has performed from one day to one year, with its 52-week range.

-4.62%
-$0.01 over 1D
$0.12$0.13$0.14$0.144:10 AM10:25 AM12:45 PM3:10 PM8:00 PM$0.12
1D
-7.59%
1W
-19.61%
1M
-47.37%
YTD
-88.82%
1Y
-85.18%
52-wk range
$0.11 – $1.45

Key statistics

Today's trading snapshot for AEON: day range, open, previous close, volume and market cap.

Day range
$0.12 – $0.13
Open
$0.13
Prev close
$0.13
Volume
1.17M
Market cap
$11.2M
Shares out
71.52M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for AEON Biopharma, Inc.: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
—
P/B
4.58
P/FCF
—
ROE
-1995.8%
ROA
-337.0%
Debt/Equity
1.21
Div yield
0.00%

As of Nov 19, 2026

8-K filings

Material corporate events AEON Biopharma, Inc. has disclosed to the SEC on Form 8-K.

  • Quarterly earningsNov 16, 2026

    On November 16, 2026, AEON Biopharma, Inc. (the "Company" or "AEON") announced financial results for the third quarter ended September 30, 2026.

  • On September 30, 2026, the Company publicly announced that it had received Type 2b meeting minutes from the U.S. Food and Drug Administration that did not preclude advancement of ABP-450 toward a Biologics License Application under the Section 351(k) biosimilar pathway, thereby triggering the accelerated expiration of the Two-Year Warrants in accordance with their terms.

  • Investor presentationOct 23, 2026

    On October 23, 2026, AEON Biopharma, Inc. made available in the investor relations section of its website a presentation (the "Corporate Presentation"), a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

  • The FDA agreed in principle with the Company's proposed two-stage design for a comparative pharmacodynamic study using Compound Muscle Action Potential ("CMAP") measurement in the extensor digitorum brevis muscle, consisting of an initial dose-finding stage followed by a comparative pharmacodynamic evaluation. The FDA provided recommendations intended to strengthen the study's ability to demonstrate assay sensitivity.

  • On August 3, 2026, the Company received a letter from NYSE Regulation confirming that the Company has regained compliance with the continued listing standards of NYSE American. The letter stated that the Company is in compliance with all of the NYSE American continued listing standards set forth in Part 10 of the NYSE American Company Guide.

Dividend history and stock splits

AEON Biopharma, Inc.'s recent dividend payments and stock splits.

Dividends

No recent dividends.

Splits

  • 1-for-72Feb 26, 2025

AEON short interest

How heavily AEON is shorted: shares short, days to cover and average daily volume.

Days to cover
6.4
Short interest
2.66M
Avg volume
415.78K

As of · reported to FINRA twice monthly.

AEON news

The latest news and headlines about AEON Biopharma, Inc. (AEON).

Frequently asked questions

What is the AEON Biopharma, Inc. (AEON) stock price today?

AEON Biopharma, Inc. (AEON) is trading at $0.1230 (-7.59% on the day) as of 8:00:00 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is AEON Biopharma, Inc.?

AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications.

What is the short interest in AEON?

As of Oct 30, 2026, AEON has 2.66M shares short and 6.4 days to cover.

What exchange is AEON listed on?

AEON Biopharma, Inc. (AEON) trades on NYSE American in USD, in the PHARMACEUTICAL PREPARATIONS industry.

Build with AI

Build an analysis of AEON with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a AEON analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.